PreveCeutical Medical, Inc. engages in licensing, branding, and marketing of nutraceutical and wellness products. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2016-12-30. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, and BSV Peptide Program. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). Its Nature Identical peptides used for treatment of various ailments. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity.
最新の財務諸表(Form-10K)によると、Preveceutical Medical Incの総資産は$0で、純損失は$0です。
PRVCFの主要な財務比率は何ですか?
Preveceutical Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Preveceutical Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
Preveceutical Medical Inc の最大収益セグメントは Deposits Software and Hardware で、最新の利益発表における収益は 74,108,000 です。地域別に見ると、United States が Preveceutical Medical Inc の主要市場であり、収益は 135,344,000 です。
Preveceutical Medical Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Preveceutical Medical Incの純損失は$0です。